These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29705017)

  • 1. Treatment Satisfaction of Patients With Advanced Non-Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL).
    Visser S; de Mol M; Cheung K; van Toor JJ; van Walree NC; Stricker BH; Den Oudsten BL; Aerts JGJV
    Clin Lung Cancer; 2018 Jul; 19(4):e503-e516. PubMed ID: 29705017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer.
    de Mol M; Visser S; den Oudsten BL; Lodder P; van Walree N; Belderbos H; Aerts JG
    Support Care Cancer; 2019 Sep; 27(9):3563-3572. PubMed ID: 30690684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer.
    Saranya K; Sreejith K; Ajaykumar
    J Oncol Pharm Pract; 2019 Dec; 25(8):1853-1859. PubMed ID: 30616471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
    de Mol M; Visser S; Aerts J; Lodder P; van Walree N; Belderbos H; den Oudsten B
    BMC Cancer; 2020 May; 20(1):431. PubMed ID: 32423432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer.
    Cheung K; de Mol M; Visser S; Den Oudsten BL; Stricker BH; Aerts JG
    Qual Life Res; 2016 Jan; 25(1):71-80. PubMed ID: 26195317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
    Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
    Galetta D; Cinieri S; Pisconti S; Gebbia V; Morabito A; Borsellino N; Maiello E; Febbraro A; Catino A; Rizzo P; Montrone M; Misino A; Logroscino A; Rizzi D; Di Maio M; Colucci G
    Clin Lung Cancer; 2015 Jul; 16(4):262-73. PubMed ID: 25582493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
    J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
    Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
    Schmid-Bindert G; Engel-Riedel W; Reck M; Schuette W; Stöhlmacher J; Fischer JR; Mazières J; Chouaid C; Wolf M; Vinolas N; Soldatenkova V; Ripoche V; Nguyen T; Visseren-Grul C
    Lung Cancer; 2015 Dec; 90(3):397-404. PubMed ID: 26791798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
    Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
    Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
    Li N; Jin ZL; Liu ZJ; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.
    Cortellini A; Gambale E; Cannita K; Brocco D; Parisi A; Napoleoni L; Masedu F; Irtelli L; De Tursi M; Natoli C; Ficorella C
    Thorac Cancer; 2018 Feb; 9(2):241-252. PubMed ID: 29388383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
    Maneechawakajorn J; Hathaisanguan S
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
    Smit E; Moro-Sibilot D; Carpeño Jde C; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
    Lung Cancer; 2016 Feb; 92():35-40. PubMed ID: 26775594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
    J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
    Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
    Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.